JNJ-75276617 (G024)

DRUG2 trials

Sponsors

Janssen - Cilag International

Conditions

Acute LeukemiaAcute Myeloid Leukemia

Phase 1

A Phase 1/2, First-in-Human Study of theMenin-KMT2A (MLL1)Inhibitor Bleximenib in Participants with Acute Leukemia

RecruitingCTIS2023-506581-31-00

Janssen - Cilag InternationalAcute Leukemia

Start: 2021-06-15Target: 86Updated: 2026-01-20

A Phase 1b Study of Bleximenib in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations

Active, not recruitingCTIS2023-506582-58-00

Janssen - Cilag InternationalAcute Myeloid Leukemia

Start: 2022-07-21Target: 86Updated: 2025-10-03